Physicians' Academy for Cardiovascular Education

ESC/EAS statin eligibility criteria in primary prevention should include very high TG levels

Unmet need for primary prevention in individuals with hypertriglyceridaemia not eligible for statin therapy according to European Society of Cardiology/European Atherosclerosis Society guidelines: a contemporary population-based study

Madsen CM, Varbo A, Nordestgaard BG. - Eur Heart J 2017; published online ahead of print

Background

Genetic studies and RCTs have demonstrated a causal association between high TG concentrations and triglyceride-rich lipoproteins and atherosclerotic CV disease (ASCVD), which cannot be explained by the inverse association between TGs and HDL-C [1]. However, no studies have assessed the impact of TG-lowering on ASCVD risk in primary prevention, and in the 2016 ESC/EAS guidelines, no definite recommendations are given on initiation of lipid-lowering therapy based on high TG levels [2].

In this analysis of the Copenhagen General Population Study (CGPS), the absolute risk of ASCVD was determined in 58 547 individuals who were divided into subgroups according to statin eligibility and TG concentrations. CGPS participants aged 40–65 years, without ASCVD, DM, or statin use at baseline, were included in the analysis and followed for a median of 8 years, and participants on statins, were evaluated for their statin eligibility, based on the 2016 ESC/EAS guidelines [2]. Individuals with very high risk and LDL-C ≥ 1.8 mmol/L (70 mg/dL) or with high risk and LDL-C ≥ 2.6 mmol/L (100 mg/dL) were defined as definite statin eligible. For comparison, individuals were also assigned to definite statin eligibility based on the 2013 ACC/AHA guidelines and the 2016 USPSTF recommendations [3,4](results not shown here).

ASCVD risk was calculated based on age, gender, smoking status, SBP, DBP, TC, LDL-C, HDL-C, and chronic kidney disease, according to guidelines [5]. The SCORE low-risk equations were used without HDL-C, but HDL-C levels were incorporated for sensitivity analyses. The endpoints were MI, and the composite MACE, including CV death, non-fatal MI, unstable angina pectoris and stroke.

Main results

Conclusion

In a large population-based study, high TG levels identified individuals at high risk of ASCVD, who would not be definite eligible for statin treatment according to the 2016 ESC/EAS guidelines. These results suggest that guidelines on statin eligibility in primary prevention might have to be expanded to individuals with hypertriglyceridemia.

References

Show references

Find this article online at Eur Heart J